SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Myriad Genetics, Inc. (MYGN)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
2355 65 0 MYGN
Emcee:  s myers Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
505>Inhibition of neurokinin-1-receptors activation with neurokinin-1-receptor afred hayes-12/14/2004
504eat all the beef you like, but be sure to take your prophylactic...... J Neuroiscaram(o)uche-12/14/2004
503240K shares, first hour of trading. Nice change.scaram(o)uche-12/14/2004
502I love the smell of Avalon roasting in the morning.scaram(o)uche-12/13/2004
501The only royalty guidance that I've heard? It's modest. MAXM will showscaram(o)uche-12/9/2004
500<i>Myriad was extremely diligent in progressing this compound to an IND, anigel bates-12/9/2004
499>> All chemistry, lead optimization and preclinical development on the comscaram(o)uche-12/9/2004
498<i>The Maxim version...</i> SAN DIEGO--(BUSINESS WIRE)--Dec. 9, 200nigel bates-12/9/2004
497Myriad Genetics Submits IND on MPC-6827 Cancer Drug Thursday December 9, 6:30 amnigel bates-12/9/2004
496piper does seem to have some voice in small bio-land, whether warranted or not, mopgcw-12/8/2004
495wow...... this Tenthoff guy has a long reach. that upgrade?..... completelscaram(o)uche-12/8/2004
494<i>sort of vague re. "and in the immunopathogenesis of HIV disease&quscaram(o)uche-12/8/2004
493United States Patent 6,828,421 Sugiyama December 7, 2004 ----------------scaram(o)uche-12/7/2004
492United States Patent 6,828,112 Manfredi , et al. December 7, 2004 -----scaram(o)uche-12/7/2004
491Piper: MYGN :Upgrading Myriad To Outperform Ahead Of Alzheimer's Data Decmopgcw-12/7/2004
490piper upgrades to outperform w/ $30 target...will pull the report from bloombergmopgcw-12/6/2004
489"anonymous" is getting eaten alive. with 6827 anecdote just around thscaram(o)uche-12/2/2004
488parking, no direct relevance....... Pulm Pharmacol Ther. 2004 Dec;17(6):347-350scaram(o)uche-11/28/2004
487<i>Riddle: What biotech CEO makes David Robinson look sharp?</i> HDoc Bones-11/28/2004
486Yeah, the entire team -- obviously including Meldrum -- seems to be firing on alscaram(o)uche-11/27/2004
485Whatever Meldrum is doing, it's not hurting the stock price very much. It&#tom pope-11/27/2004
484Meldrum: Short interest (declared) continues to decline. It's down 16% forscaram(o)uche-11/27/2004
483<pre>Month Short Interest Percent Change Average Daily Share Volume Dayscaram(o)uche-11/27/2004
482short interest just keeps going down, but there's never a form SC 13 showingscaram(o)uche-11/24/2004
481Allowed to wander with ^btk all day long, "anonymous" steps in, locks scaram(o)uche-11/24/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News